Evidence-based mechanistic reasoning
暂无分享,去创建一个
[1] Sharon E Straus,et al. Evidence-Based Medicine: How to Practice and Teach It , 2010 .
[2] F. Miller. Death and organ donation: back to the future , 2009, Journal of Medical Ethics.
[3] J. Howick. Questioning the Methodologic Superiority of ‘Placebo’ Over ‘Active’ Controlled Trials , 2009, The American journal of bioethics : AJOB.
[4] A. Osterhaus,et al. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. , 2009, Biologicals : journal of the International Association of Biological Standardization.
[5] R. Truog,et al. The Incoherence of Determining Death by Neurological Criteria: A Commentary on Controversies in the Determination of Death, A White Paper by the President’s Council on Bioethics , 2009, Kennedy Institute of Ethics journal.
[6] J. Howick. Escaping from placebo prison , 2009, BMJ : British Medical Journal.
[7] Paul Glasziou,et al. The evolution of evidence hierarchies: what can Bradford Hill's ‘guidelines for causation’ contribute? , 2009, Journal of the Royal Society of Medicine.
[8] M. Kringelbach,et al. Deep brain stimulation: avoiding the errors of psychosurgery. , 2009, JAMA.
[9] Gordon H Guyatt,et al. Epistemologic inquiries in evidence-based medicine. , 2009, Cancer control : journal of the Moffitt Cancer Center.
[10] R. Prentice. Surrogate and mediating endpoints: current status and future directions. , 2009, Journal of the National Cancer Institute.
[11] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[12] Douglas G Altman,et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.
[13] L. Hegedüs,et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. , 2007, The Journal of clinical endocrinology and metabolism.
[14] Paul Glasziou,et al. When are randomised trials unnecessary? Picking signal from noise , 2007, BMJ : British Medical Journal.
[15] Manfred Hauben,et al. Anecdotes that provide definitive evidence , 2006, BMJ : British Medical Journal.
[16] Ike Iheanacho,et al. Testing Treatments: Better Research for Better Healthcare , 2006, BMJ : British Medical Journal.
[17] N. Shah,et al. The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. , 2005, Journal of clinical epidemiology.
[18] Donald Gillies,et al. Hempelian and Kuhnian approaches in the philosophy of medicine: the Semmelweis case. , 2005, Studies in history and philosophy of biological and biomedical sciences.
[19] V. Stenger,et al. Retroactive prayer: lots of history, not much mystery, and no science , 2004, BMJ : British Medical Journal.
[20] G. Lüchters,et al. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.
[21] C. Biscayart,et al. Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine. , 2003, Vaccine.
[22] John P A Ioannidis,et al. Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.
[23] B. Dikici,et al. Accelerated hepatitis B vaccination schedule in childhood , 2002, Pediatrics international : official journal of the Japan Pediatric Society.
[24] D. Moher,et al. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study , 2002, BMC health services research.
[25] J. Karlawish,et al. The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.
[26] D. Altman. Poor-quality medical research: what can journals do? , 2002, JAMA.
[27] M. Dietrich,et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. , 2002, Vaccine.
[28] H. Huikuri,et al. Sudden death due to cardiac arrhythmias. , 2001, The New England journal of medicine.
[29] P. Machamer,et al. Thinking about Mechanisms , 2000, Philosophy of Science.
[30] G. Gamble,et al. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. , 2000, Diabetes care.
[31] R. Lilford,et al. The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals , 1998, BMJ.
[32] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[33] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[34] A. Paes,et al. Impact of Dosage Frequency on Patient Compliance , 1997, Diabetes Care.
[35] S. Satya‐Murti. Evidence-based Medicine: How to Practice and Teach EBM , 1997 .
[36] R. Davis,et al. Prone sleep position and the sudden infant death syndrome in King County, Washington: a case-control study. , 1996, The Journal of pediatrics.
[37] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[38] D G Altman,et al. The scandal of poor medical research , 1994, BMJ.
[39] T. Dwyer,et al. Factors potentiating the risk of sudden infant death syndrome associated with the prone position. , 1993, The New England journal of medicine.
[40] A. Detsky,et al. Evidence-based medicine. A new approach to teaching the practice of medicine. , 1992, JAMA.
[41] A. Zuckerman,et al. Hepatitis B surface antigen polypeptide micelles from antigen expressed in Saccharomyces cerevisiae. , 1986, Journal of virological methods.
[42] J. Aronson,et al. Oxford Textbook of Clinical Pharmacology and Drug Therapy , 1985 .
[43] T. Eisenstein,et al. Hepatitis B: The Virus, the Disease, and the Vaccine , 1984 .
[44] M. Hilleman,et al. Human hepatitis B vaccine from recombinant yeast , 1984, Nature.
[45] D. S. Dane,et al. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. , 1970, Lancet.
[46] K. Popper,et al. Conjectures and refutations;: The growth of scientific knowledge , 1972 .
[47] R. Asher. Apriority: thoughts on treatment. , 1961, Lancet.
[48] B. Spock. Baby and Child Care , 1959 .
[49] J. I. The Design of Experiments , 1936, Nature.
[50] T. Fahey. Transient Goiter Enlargement after Administration of 0.3 mg of Recombinant Human Thyrotropin in Patients with Benign Nontoxic Nodular Goiter: A Randomized, Double-Blind, Crossover Trial , 2007 .
[51] J. Aronson,et al. Paradoxical reactions: Under-recognized adverse effects of drugs? , 2006 .
[52] B. Marshall. Helicobacter Connections , 2006, ChemMedChem.
[53] Duff R. Waring. Paradoxical Drug Response and the Placebo Effect: A Discussion of Grunbaum's Definitional Scheme , 2003, Theoretical Medicine and Bioethics.
[54] Gordon H. Guyatt,et al. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice; Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice , 2003, BMJ : British Medical Journal.
[55] B. Schmidt,et al. Do we measure the right end points? A systematic review of primary outcomes in recent neonatal randomized clinical trials. , 2001 .
[56] J. Cramer. Enhancing Patient Compliance in the Elderly , 1998, Drugs & aging.
[57] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.